
    
      Patients will be randomized in a 1:1 ratio to receive one of two different treatment arms.
      Patients in treatment arm 1 will receive AC followed by ixabepilone. Patients in treatment
      arm 2 will receive AC followed by weekly paclitaxel.
    
  